Medwave Inc.'s Technology Studied In Difficult Liver Transplant Cases Published In Anesthesia & Analgesia

DANVERS, Mass., March 10 /PRNewswire-FirstCall/ -- Medwave, Inc. , the innovator in sensor-based, non-invasive blood pressure measuring solutions, announced today that a study titled "Vasotrac Arterial Pressure and Direct Arterial Pressure Monitoring During Liver Transplantation" has been published in the March 2006 issue of Anesthesia & Analgesia. The study was conducted at The Mayo Clinic in Rochester, Minnesota by James Y. Findlay, FRCA, Bhargavi Gali, MD, Mark T. Keegan, MRCPI, Christopher M. Burke, MD, and David J. Plevak, MD.

Rich Niemczyk, Vice President of Support Services, commented, "While the conclusion of the study stated that the Vasotrac was not an adequate replacement for direct arterial blood pressure monitoring in liver transplant patients, the statistical correlation for 6468 readings during up to 7.5 hour procedures was still impressive. In previous studies from other institutions comparing Vasotrac to arterial catheters, the correlation was much tighter. The hemodynamic complexity of the patient undergoing a liver transplant, as the authors point out in the discussion portion of the paper, is such that eliminating direct arterial pressure monitoring is a lofty goal for this patient population. Additionally, it should be pointed out that the Vasotrac correlation in this study was closer than most studies using a cuff to arterial line comparison, even in less severe patients. While others have reported a decrease in use of arterial catheters due to the ability of the Vasotrac monitor, it is not our goal as a company to eliminate these devices, rather we are concentrating our efforts on being a replacement for the antiquated BP cuff technologies."

Medwave, Inc. develops, manufactures, and distributes sensor-based non- invasive blood pressure solutions. The company's suite of products are designed for use in hospitals, clinics, doctor's offices and almost anywhere else blood pressure monitoring takes place. Medwave has the required technology clearances to market its technology in the United States, Europe, and Asia, and Medwave's technology is installed in over 500 hospitals and clinics worldwide. Medwave trades on the NASDAQ small cap market under the symbol MDWV. For more information, visit http://www.medwave.com .

Statements made in this release that are stated as expectations, plans, anticipations, prospects or future estimates or which otherwise look forward in time are considered "forward-looking statements" and involve a variety of risks and uncertainties, known and unknown, which are likely to affect the actual results. The following factors, among others, as well as factors discussed in Medwave's filings with the SEC, have affected and, in the future, could affect Medwave's actual results: resistance to the acceptance of new medical products, the market acceptance of the Primo(TM) system, the Vasotrac(R) system and other products of Medwave, hospital budgeting cycles, the possibility of adverse or negative results or commentary from clinical researchers or other users or evaluators of Medwave's products, Medwave's success in creating effective distribution channels for its products, Medwave's ability to scale up its manufacturing process, and delays in product development or enhancement or regulatory approval. Consequently, no forward- looking statement can be guaranteed and actual results may vary materially. Medwave(R), Vasotrac(R), Legato(TM), and Primo(TM) are trademarks of Medwave, Inc.

Medwave, Inc.

CONTACT: Investor Relations, Jodie Chastain, +1-800-894-7601, or MediaRelations, Kevin Sawyer, +1-612-465-8356, both for Medwave, Inc.

Back to news